Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia
Status:
Not yet recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety and efficacy of fractionated ablative
10,600nm CO2 laser assisted delivery of 2% minoxidil solution in the treatment of MPHL. In
this cohort study, patients will randomly be assigned stand-alone laser treatment, laser
assisted drug delivery of minoxidil 2% solution, and laser assisted drug delivery of
minoxidil 2% solution plus at home 5% minoxidil treatment. The primary endpoints will be to
assess the change from baseline in investigator and subject Hair Growth Assessments (HGA),
Hair Growth Index (HGI) and the Hair Growth Satisfaction Scale (HGSS) over 8-12 weeks in each
of the three groups. The secondary endpoints will be expert assessment of hair density from
baseline and evaluation of safety and adverse events, and pharmacokinetic (PK) data.
Phase:
Phase 2
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute